Pepteligence
Share
Medical notice — For research and educational purposes only. Not medical advice. Consult a licensed physician before using any peptide or compound.

MOTS-c

metabolicmitochondrialongevity
Regulatory status — Research use only — not approved for human use

MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded within the 12S rRNA region of mitochondrial DNA that acts as a regulator of cellular energy metabolism and stress adaptation [1] [2]. Preliminary animal and in vitro evidence suggests it may improve insulin sensitivity, enhance skeletal muscle glucose metabolism, and exert cardioprotective effects, though no human clinical trials have been conducted [4] [5]. MOTS-c remains a research-only compound with no regulatory approval, no established human dosing data, and no clinical safety profile.

Evidence coverage

40/47 claims verified by independent fact-checker.

Pepteligence regenerates entries quarterly and when new high-tier evidence appears.

Quick facts

Half-life
—
Typical dose
See research context
Route
[insufficient evidence in research packet]
Frequency
[insufficient evidence in research packet]
Cycle length
—
Evidence strength
Animal models

Suggested labs for this peptide class — educational reference only; not medical advice.

TL;DR

  • Half-life: — — dosed —.
  • Administered via —.
  • Evidence base: animal model studies.
  • Primary goals: metabolic, mitochondria, longevity.
EVIDENCE HIERARCHYRCTsObservationalAnimal studiesAnecdotal

Primarily animal data

How we evaluate evidence →

How it works

GHRH analogues stimulate pulsatile GH release from the pituitary, elevating IGF-1 and promoting fat oxidation.

MOTS-c is a 16-amino acid peptide encoded by the 12S rRNA region of mitochondrial DNA, making it one of a small class of mitochondrial-derived peptides with systemic signaling functions [1] [2]. Animal and mechanistic studies indicate it acts primarily through the Folate-AICAR-AMPK signaling pathway to regulate cellular energy metabolism and stress adaptation [2] [17] [3]. During metabolic stress, MOTS-c translocates from the mitochondria to the nucleus, where it appears to regulate the expression of stress adaptation-related genes containing antioxidant response elements [1] [2]. Animal studies indicate that MOTS-c enhances skeletal muscle glucose uptake and metabolism through AMPK-dependent mechanisms [17] [5] [6] and improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner [15]. Adiponectin has been shown in mice to regulate MOTS-c expression in skeletal muscle through the APPL1-SIRT1-PGC-1α pathway, linking it to broader metabolic signaling networks [3]. Animal studies also suggest MOTS-c alters plasma metabolite profiles in obese mice by reducing sphingolipid, monoacylglycerol, and dicarboxylate metabolism pathways [4]. In a rodent model, MOTS-c was found to prime adrenal cortex metabolism without directly driving steroidogenesis [19], and in mice it appears to target SLC7A11 to preserve spermatogenesis by suppressing ferroptosis [20]. All mechanistic data described here derive from animal or in vitro studies; the relevance of these pathways to human physiology has not been established in clinical trials.

What the research says

Research summary content coming soon. Check the references section for indexed studies.

100%50%25%0%00h1t½0h2t½0h3t½0h4t½0h
Approximate plasma concentration over 4 half-lives (0h × 4 = 0h)

Protocol lifecycle

BeforeDuringAfter

Before — Pre-cycle readiness

Readiness checklist

Medical evaluation
  • Discuss use with a licensed clinician knowledgeable in peptide pharmacology.
  • Disclose all medications and supplements; no interaction data exist for MOTS-c in humans.
  • Obtain baseline metabolic labs (fasting glucose, insulin, HbA1c, lipid panel) given proposed mechanisms.
Understanding the evidence gap
  • Acknowledge that no human clinical trials of MOTS-c have been published.
  • Acknowledge that no human pharmacokinetic, dosing, or safety data exist.
  • Understand that all efficacy signals come from animal or in vitro studies and may not translate to humans.
Regulatory awareness
  • MOTS-c is not approved by the FDA, EMA, or Health Canada for any indication.
  • Confirm the legal status of research peptides in your jurisdiction before procurement.
  • No evidence-based preparation protocol exists for MOTS-c in humans. Consult a qualified clinician before considering use.
  • Consider baseline metabolic panel (fasting glucose, insulin, HOMA-IR) given the compound's proposed metabolic mechanisms [2].
  • Individuals with known mitochondrial polymorphisms (e.g., m.1382A>C) may face differential risk and should exercise additional caution [8].

During — Active protocol

Protocol notice — The following describes common protocols reported in research and community sources. This is not medical advice. Dosing, frequency, and duration should be determined with a licensed physician familiar with peptide research.
  • No evidence-based monitoring protocol exists for MOTS-c use in humans.
  • Animal studies suggest synergistic interaction with exercise on PGC-1α expression and glucose metabolism [5]; clinical relevance is unknown.
  • High and moderate-intensity interval exercise independently increases mitochondrial MOTS-c expression in animal models and correlates with improved metabolic markers [14]; whether exogenous MOTS-c modifies this relationship in humans is unknown.

After — Post-cycle

  • No cycling, washout, or post-cycle protocol is supported by evidence in humans.
  • Given the absence of human pharmacokinetic data, no guidance on duration or cessation can be provided.

Stacks it appears in

MOTS-c is typically used as a standalone compound. Stack data coming soon.

Related peptides

Other compounds indexed on Pepteligence that share research tags with MOTS-c. Educational context only.

Epitalon

Tier 3
longevity

Tirzepatide

Tier 1
metabolic

Semaglutide

Tier 1
metabolic

Tesamorelin

Tier 1
metabolic

Safety

Common side effects

  • ·No human data available. Common side effects cannot be characterized from the existing evidence base.

Rare side effects

  • ·No human data available.
Safety notice — Serious / theoretical risks:
  • No human data available. The absence of reported serious adverse events reflects the absence of human trials, not confirmed safety.

Contraindications

  • ·No absolute contraindications have been identified in the research packet; however, no human safety studies have been conducted.
  • ·Individuals carrying the m.1382A>C (rs111033358) mtDNA polymorphism may be at differential risk; this variant is associated with increased type 2 diabetes risk in males and produces a functionally distinct K14Q MOTS-c variant [8].
  • ·Pregnancy and breastfeeding: no safety data exist; use cannot be supported.
  • ·Pediatric populations: no safety or dosing data exist.

Community experiences

Community content — User-submitted experiences are self-reported and have not been verified. They do not constitute medical advice. Pepteligence aggregates community data under Section 230 protections.

No community experiences yet for MOTS-c. Be the first to share yours.

Share your experience →

Have you tried MOTS-c?

Share your protocol and outcome to help build the community dataset.

Share your experience →

MOTS-c — at a glance

PropertyMOTS-c—
Half-life——
Route——
Typical doseSee research context—
MechanismMOTS-c is a 16-amino acid peptide encoded by the 12S rRNA region of mitochondrial DNA, making it one of a small class of mitochondrial-derived peptides with systemic signaling functions. Animal and mechanistic studies indicate it acts primarily through the Folate-AICAR-AMPK signaling pathway to regulate cellular energy metabolism and stress adaptation. During metabolic stress, MOTS-c translocates from the mitochondria to the nucleus, where it appears to regulate the expression of stress adaptation-related genes containing antioxidant response elements. Animal studies indicate that MOTS-c enhances skeletal muscle glucose uptake and metabolism through AMPK-dependent mechanisms and improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Adiponectin has been shown in mice to regulate MOTS-c expression in skeletal muscle through the APPL1-SIRT1-PGC-1α pathway, linking it to broader metabolic signaling networks. Animal studies also suggest MOTS-c alters plasma metabolite profiles in obese mice by reducing sphingolipid, monoacylglycerol, and dicarboxylate metabolism pathways. In a rodent model, MOTS-c was found to prime adrenal cortex metabolism without directly driving steroidogenesis, and in mice it appears to target SLC7A11 to preserve spermatogenesis by suppressing ferroptosis. All mechanistic data described here derive from animal or in vitro studies; the relevance of these pathways to human physiology has not been established in clinical trials.—
Evidence strengthanimalanecdotal
Primary goalmetabolic—

Frequently asked questions

What is MOTS-c?
MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded within the 12S rRNA region of mitochondrial DNA. It acts as a regulator of cellular energy metabolism and stress adaptation. It is not FDA-approved and all current evidence comes from animal and mechanistic studies.
How does MOTS-c work?
MOTS-c acts primarily through the Folate-AICAR-AMPK signaling pathway to regulate cellular metabolism and energy homeostasis. Animal and mechanistic studies indicate it influences mitochondrial function and metabolic stress responses. These findings come from animal and in vitro research — no controlled human trials have validated these mechanisms.
What is MOTS-c used for?
Animal and mechanistic research has investigated MOTS-c for roles in cellular energy metabolism regulation and stress adaptation. No controlled human clinical trials have established efficacy or safety for any indication.
Is MOTS-c FDA-approved?
No. MOTS-c is not FDA-approved for any indication. No human safety studies have been conducted to establish its clinical profile.
Is MOTS-c naturally occurring?
Yes. MOTS-c is an endogenously produced mitochondrial-derived peptide encoded by the mitochondrial genome and present in human plasma and tissues. It is part of a recently identified class of bioactive peptides encoded by mitochondrial DNA that participate in mitochondria-to-nucleus signaling.
What are common dosages of MOTS-c?
No human clinical dosing data exist for MOTS-c. No approved or consensus dose could be identified from the available research literature.
How is MOTS-c administered?
No validated route of administration has been established for MOTS-c in human clinical research. The research packet documents insufficient evidence to identify a confirmed administration route.
What are common side effects of MOTS-c?
No controlled human clinical trial data exist to characterize MOTS-c's side-effect profile. No human safety studies have been conducted.
Are there safety concerns with MOTS-c?
No absolute contraindications have been identified, but no human safety studies have been conducted. Individuals carrying the m.1382A>C (rs111033358) mitochondrial DNA polymorphism may be at differential risk, as this variant produces a functionally distinct K14Q MOTS-c isoform and is associated with increased type 2 diabetes risk in males. Pregnancy and breastfeeding use cannot be supported given the absence of safety data.
Is MOTS-c legal?
MOTS-c is not FDA-approved and is not a scheduled controlled substance in the United States. Its legal status for possession and sale varies by jurisdiction. This is not legal advice.
Can MOTS-c be combined with other compounds?
No evidence-supported combination protocols have been established for MOTS-c. The current source literature does not document any stacking combinations with human-validated data.
What makes MOTS-c unique compared to other peptides?
MOTS-c is classified as a mitochondrial-derived peptide (MDP) — it is encoded within the mitochondrial genome rather than the nuclear genome. This makes it part of a small, recently identified class of bioactive peptides that contribute to mitochondria-to-nucleus signaling, distinct from conventionally synthesized peptides.

References

  1. [1]

    MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.

    Zheng Yuejun, Wei Zilin, Wang Tianhui

    Frontiers in endocrinology · 2023 · PMID 36761202

    View on PubMed →
  2. [2]

    Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging.

    Wan Wei, Zhang Lieliang, Lin Yue et al.

    Journal of translational medicine · 2023 · PMID 36670507

    View on PubMed →
  3. [3]

    Adiponectin treatment improves insulin resistance in mice by regulating the expression of the mitochondrial-derived peptide MOTS-c and its response to exercise via APPL1-SIRT1-PGC-1α.

    Guo Qi, Chang Bo, Yu Qiong-Li et al.

    Diabetologia · 2020 · PMID 32880686

    View on PubMed →
  4. [4]

    The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity.

    Kim Su-Jeong, Miller Brendan, Mehta Hemal H et al.

    Physiological reports · 2019 · PMID 31293078

    View on PubMed →
  5. [5]

    MOTS-c interacts synergistically with exercise intervention to regulate PGC-1α expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway.

    Yang Boyu, Yu Qiongli, Chang Bo et al.

    Biochimica et biophysica acta. Molecular basis of disease · 2021 · PMID 33722744

    View on PubMed →
  6. [6]

    The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.

    Yin Yadong, Pan Yihui, He Jin et al.

    Pharmacological research · 2022 · PMID 34798268

    View on PubMed →
  7. [7]

    Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals.

    Cataldo Luis Rodrigo, Fernández-Verdejo Rodrigo, Santos José Luis et al.

    Journal of investigative medicine · 2018 · PMID 29593067

    View on PubMed →
  8. [8]

    A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c.

    Zempo Hirofumi, Kim Su-Jeong, Fuku Noriyuki et al.

    Aging · 2021 · PMID 33468709

    View on PubMed →
  9. [9]

    The relationship of circulating MOTS-c level with liver fibrosis and metabolic components in patients with metabolic dysfunction-associated fatty liver disease.

    Kirik A, Dogru T, Yanik B et al.

    European review for medical and pharmacological sciences · 2023 · PMID 37750635

    View on PubMed →
  10. [10]

    Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?

    Filibeli Berna Eroğlu, Dedemoglu Fatima, Garipcin Pinar et al.

    Archives of endocrinology and metabolism · 2026 · PMID 41945630

    View on PubMed →
  11. [11]

    Reduced serum and skeletal muscle MOTS-c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction.

    Kutuk Irem Sonmezoglu, Akin Senay, Demirel Haydar et al.

    Scientific reports · 2026 · PMID 41680431

    View on PubMed →
  12. [12]

    Relationship between the mitochondria-derived peptide MOTS-c and insulin resistance in obstructive sleep apnea.

    Baylan Filiz Alkan, Yarar Esra

    Sleep & breathing · 2021 · PMID 33394327

    View on PubMed →
  13. [13]

    Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss.

    Yoon Se-Hee, Yuan Fei, Zhu Xiangyang et al.

    Journal of clinical & translational endocrinology · 2026 · PMID 41551324

    View on PubMed →
  14. [14]

    An 8-Week study on the effects of high and Moderate-Intensity interval exercises on mitochondrial MOTS-C changes and their relation to metabolic markers in male diabetic sand rats.

    Parseh Sahar, Shakerian Saeid, Reza Tabandeh Mohammad et al.

    Diabetes research and clinical practice · 2024 · PMID 38636847

    View on PubMed →
  15. [15]

    MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner.

    Gudiksen Anders, Hansen Camilla Collin, van der Stede Thibaux et al.

    Free radical biology & medicine · 2026 · PMID 41520850

    View on PubMed →
  16. [16]

    Exogenous MOTS-c mitigates myocardial ischemia-reperfusion injury: experimental and in silico evidence from rat heart models.

    Santhanam Saranya Sri, Jayaraman Srijan, Kurian Gino A

    Naunyn-Schmiedeberg's archives of pharmacology · 2026 · PMID 41593376

    View on PubMed →
  17. [17]

    Aerobic exercise and MOTS-c attenuate diabetic myocardial fibrosis via inhibition of the THBS1/TGF-β signaling pathway.

    Li Zhiyu, Wang Tutu, Fu Yu et al.

    Frontiers in endocrinology · 2026 · PMID 41710402

    View on PubMed →
  18. [18]

    MOTS-c and Exercise Restore Cardiac Function by Activating of NRG1-ErbB Signaling in Diabetic Rats.

    Li Shunchang, Wang Manda, Ma Jiacheng et al.

    Frontiers in endocrinology · 2022 · PMID 35370955

    View on PubMed →
  19. [19]

    MOTS-c primes adrenal cortex metabolism without directly driving steroidogenesis.

    Blatkiewicz Malgorzata, Kaminski Kacper, Sobalska-Kwapis Marta et al.

    Folia histochemica et cytobiologica · 2026 · PMID 41811086

    View on PubMed →
  20. [20]

    Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis.

    Liu Shuai, Ru Kang, Shen Yu-Jie et al.

    Free radical biology & medicine · 2026 · PMID 41933740

    View on PubMed →
  21. [?]

    MOTS-C levels in individuals with and without obesity and its association with inflammation, insulin resistance and endothelial dysfunction.

    Ozkaya Duygu Yildiz, Haymana Cem, Demirci Ibrahim et al.

    Archives of endocrinology and metabolism · 2025 · PMID 41004666

    View on PubMed →
  22. [?]

    Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Dynamics as a Complementary Marker of Treatment Response in Newly Diagnosed Multiple Myeloma: A Prospective Analysis.

    Erol Veysel, Avci Esin, Kabukcu Hacioglu Sibel et al.

    Cureus · 2025 · PMID 41479490

    View on PubMed →
  23. [?]

    Mitochondrial-derived peptides MOTS-c and humanin attenuate dexamethasone-induced atrophy in human skeletal muscle cells.

    Elhusseiny Rabie, Ihsan Mohammed, Bellefroid Théo et al.

    Physiological reports · 2026 · PMID 41732124

    View on PubMed →
  24. [?]

    Mitochondria-derived peptide MOTS-c alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice by activating Nrf2 pathway.

    Chen Dan, Zhou Mei-Hui, Zhu Wei-Ying et al.

    European journal of pharmacology · 2026 · PMID 41802484

    View on PubMed →
  25. [?]

    MOTS-c Protects Against Acetaminophen-induced Liver Injury through the MAPK Signaling Pathway.

    Li Nan, Xu Yimin, Chen Qixin et al.

    Protein and peptide letters · 2026 · PMID 41764620

    View on PubMed →
  26. [?]

    Therapeutic Effects of MOTS-c in the Valproic Acid-Induced Autism Model in Rats: Role of Tetrahydrobiopterin and Brain-Derived Neurotrophic Factor.

    Güvenir Seven Sıla, Sahin Hakan, Erkanlı Şentürk Gözde et al.

    Molecular neurobiology · 2026 · PMID 41706383

    View on PubMed →
  27. [?]

    MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy.

    Feng Zihang, Xing Yuan, Lou Jing et al.

    Free radical biology & medicine · 2026 · PMID 41654147

    View on PubMed →
  28. [?]

    MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction.

    Lu Huanyu, Wei Ming, Zhai Yue et al.

    Journal of molecular medicine (Berlin, Germany) · 2019 · PMID 30725119

    View on PubMed →
  29. [?]

    Earlier changes in mice after D-galactose treatment were improved by mitochondria derived small peptide MOTS-c.

    Li Qingyang, Lu Huanyu, Hu Guangyu et al.

    Biochemical and biophysical research communications · 2019 · PMID 30967270

    View on PubMed →